HC Wainwright Estimates Armata Pharmaceuticals FY2026 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) – Stock analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Armata Pharmaceuticals in a report released on Thursday, May 14th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($1.88) per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($3.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78). The company had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.74 million.

Armata Pharmaceuticals Trading Down 5.6%

Shares of ARMP stock opened at $7.60 on Tuesday. The company has a market capitalization of $279.00 million, a price-to-earnings ratio of -0.98 and a beta of 1.31. The firm has a 50-day moving average price of $10.30 and a 200 day moving average price of $8.18. Armata Pharmaceuticals has a twelve month low of $1.17 and a twelve month high of $16.34.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of institutional investors have recently modified their holdings of ARMP. Madison Asset Management LLC purchased a new position in shares of Armata Pharmaceuticals during the first quarter valued at approximately $21,583,000. 683 Capital Management LLC acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at $878,000. Sei Investments Co. acquired a new position in Armata Pharmaceuticals in the 1st quarter valued at $760,000. Goldman Sachs Group Inc. purchased a new position in shares of Armata Pharmaceuticals during the 4th quarter worth $284,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Armata Pharmaceuticals during the fourth quarter worth $177,000. Institutional investors and hedge funds own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.